William Lis joined Abingworth as an Operating Executive in 2023. He has over 30 years of biopharmaceutical experience and is Chairman, after serving as CEO, of Abingworth portfolio company, Jasper Therapeutics, Inc (NASDAQ:JSPR) where he led the company’s private and public financings and antibody and cell therapy pipeline from 2019 until 2022. He is a Director, Zai Laboratories, Inc (NASDAQ: ZLAB). Previously, William served as CEO of Portola Pharmaceuticals, Inc. from 2008 until 2018 after serving as COO. Under his leadership, Portola successfully grew from a discovery-stage company to a fully integrated R&D and commercial organization, and independently discovered and developed Andexxa®, Bevyxxa® and cerdulatinib. He led the IPO and grew Portola into a multi-billion-dollar valuation company. Portola was acquired by Alexion Pharmaceuticals, Inc. in 2020. William held executive positions at Scios, Inc. (a Johnson & Johnson company) where he last served as SVP of New Product Development and BD, having led in-licensing efforts, development, and the commercial P&L operations for Xarelto® and therapeutics pipeline. He held positions at Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.) and Rhone Poulenc Rorer in sales, marketing, medical affairs, and BD. He had increasing roles of responsibility for the commercial launch of Integrilin®, Lovenox®, Velcade® and Rilutek®. William served as a member of the Bio Board of Directors for Emerging Companies and as an independent Director of Eidos Therapeutics, Inc (NASDAQ:EIDX), acquired by Bridge Bio in 2020. William holds a B.S. from the University of Maryland.
